Uncategorized

Luxa Biotechnology, a joint venture between Y2 Solution Co. Ltd, Seoul, South Korea and the Neural Stem Cell Institute in Rensselaer, New York, announced receipt of a $4 million grant from the California Institute for Regeneration Medicine to support the ongoing Phase 1/2a study of RPESC-RPE-4W transplantation for the treatment of dry age-related macular degeneration.

Quest Diagnostics announced a multi-faceted collaboration designed to accelerate the adoption of digital and AI pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases.

Calidi Biotherapeutics Inc. announced the acceptance of three abstracts that will be presented in a poster session at the 2024 American Society of Clinical Oncology Annual Meeting, taking place from May 31-June 4, 2024, in Chicago, Illinois.

STAAR Surgical Company, a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses for myopia, astigmatism and presbyopia, announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel.

Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, announced its first-quarter 2024 financial results.

IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming investor relations event.

MolecuLight Inc. announces that its MolecuLight wound imaging platform is being prominently featured in several presentations and posters at the European Wound Management Association 2024 Annual Conference, being held from May 1 – 3, 2024 in London, United Kingdom.

Ventegra, Inc. announced the successful implementation of the Ventegra Specialty Inclusion program to maintain broad access for payors, providers, and members to beneficial medications at an affordable cost.

KalVista Pharmaceuticals, Inc., announced its strategic plans for fiscal year 2025, beginning May 1, including for sebetralstat, the Company’s investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.

Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2024.